Transdermal nicotine patches for eosinophilic pustular folliculitis. 2013

Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

We previously reported the clinical effectiveness of transdermal nicotine patches for the treatment of skin disorders with eosinophilic infiltration such as Kimura's disease, erythema nodosum and eosinophilic pustular folliculitis (EPF). We assessed the efficacy and safety of transdermal nicotine patches for EPF. We treated eight patients with EPF with transdermal nicotine patches and evaluated the treatment response by performing overall lesional assessment. Excellent 77and good responses were obtained in five and one patient(s), respectively. In the other two patients, the lesions remained unchanged. No severe adverse effects were observed. Our results suggest that transdermal nicotine patches may be useful and safe in the treatment of EPF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D004802 Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs. Eosinophilia, Tropical,Hypereosinophilia,Tropical Eosinophilia,Hypereosinophilias,Tropical Eosinophilias
D005260 Female Females
D005499 Folliculitis Inflammation of follicles, primarily hair follicles. Sycosis,Folliculitides,Sycoses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012872 Skin Diseases, Vesiculobullous Skin diseases characterized by local or general distributions of blisters. They are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. (From Scientific American Medicine, 1990) Bullous Skin Diseases,Pustular Dermatosis, Subcorneal,Skin Diseases, Bullous,Skin Diseases, Vesicular,Sneddon-Wilkinson Disease,Subcorneal Pustular Dermatosis,Vesicular Skin Diseases,Vesiculobullous Skin Diseases,Bullous Dermatoses,Vesiculobullous Dermatoses,Bullous Skin Disease,Dermatoses, Bullous,Dermatoses, Subcorneal Pustular,Dermatoses, Vesiculobullous,Dermatosis, Subcorneal Pustular,Pustular Dermatoses, Subcorneal,Skin Disease, Bullous,Skin Disease, Vesicular,Skin Disease, Vesiculobullous,Sneddon Wilkinson Disease,Subcorneal Pustular Dermatoses,Vesicular Skin Disease,Vesiculobullous Skin Disease

Related Publications

Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
May 2005, The British journal of dermatology,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
June 1992, Pediatrics,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
January 1970, Acta dermato-venereologica,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
October 2007, Archives of pathology & laboratory medicine,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
May 1991, Journal of the American Academy of Dermatology,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
March 1986, Journal of the American Academy of Dermatology,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
March 1986, Journal of the American Academy of Dermatology,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
March 1986, Journal of the American Academy of Dermatology,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
October 1987, Journal of the American Academy of Dermatology,
Asuka Yoshifuku, and Yuko Higashi, and Shigeto Matsushita, and Kazuhiro Kawai, and Takuro Kanekura
January 1987, Dermatologica,
Copied contents to your clipboard!